Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
SpaceX rocket launches 140 satellites into orbit on Transporter-15, aces landing at sea (video) - 2Manual for Mountain Objections on the planet
- 3The gay hockey show no one saw coming — and everyone is suddenly obsessed with
- 4A Manual for Extravagant Vehicles Available in 2024
- 5Step by step instructions to Pick the Right Dental specialist for Your Teeth Substitution
- Vote in favor of the Web-based Work out schedule to Keep You Fit and Sound
- Step by step instructions to Lessen Your Gamble of Creating Cellular breakdown in the lungs
- Tesla Stock Hasn’t Looked This Cheap in a While
- Dinosaur collagen used to create one-of-a-kind handbag
- 2024 Eurovision winner Nemo returns trophy over Israel's participation
- 6 Tire Brands Reasonable for Seniors
- Figuring out the Justification for Separation: To blame and No-Shortcoming
- Germany's Lufthansa enters race for stake in Portuguese airline TAP
- I'm a woman who's into weightlifting. Was I man enough for the creatine-packed 'Man Cereal'?
